Terms ending in 2032
Every in-force patent on CureVac AG's record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,447,431 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Therapeutic Protein In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 10,111,968 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Therapeutic Protein In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 10,166,283 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Pathogenic Antigen In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 10,610,605 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Therapeutic Protein In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 10,912,826 | Nucleic Acid Comprising or Coding for a Histone Stem-Loop and a Poly(A) Sequence or a Polyadenylation Signal for Increasing the Expression of an Encoded Pathogenic Antigen In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 10,172,935 | Vaccination in Newborns and Infants In force · High confidence | Curevac SE | In force | High confidence | |
| US 10,596,252 | Vaccination in Newborns and Infants In force · High confidence | Curevac SE | In force | High confidence | |
| US 10,729,761 | Vaccination in Newborns and Infants In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 11,672,856 | Vaccination in Newborns and Infants In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,975,064 | VACCINATION WITH mRNA-CODED ANTIGENS In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| 9 more term ends in 2032 · Pro | |||||
10 of 19 patents shown. Soonest term end first, then patent number.
Pro members see all 19.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.